Article One
Note: While our most popular guides have been translated into Spanish, some guides are only available in English.

Is there any human data available on Basis? Has it been published?

Yes. Elysium conducted a first-in-humans, double-blind, placebo-controlled, randomized study assessing the safety and efficacy of taking repeat doses of Basis — a combination of nicotinamide riboside (NR) and pterostilbene — in a population of 120 healthy adults ages 60-80. Participants taking the recommended dose of Basis (250 mg of NR; 50 mg of pterostilbene) saw their NAD+ levels increase by an average of 40 percent over baseline after 30 days, a number that was sustained at 60 days. Participants taking twice the recommended dose of Basis saw their NAD+ levels increase by 90 percent over baseline after 30 days and 55 percent at 60 days. Those taking the placebo saw no NAD+ increase at all. There were no serious adverse events reported in the study.


The clinical study was published in November 2017 in Nature Partner Journals: Aging and Mechanisms of Disease, an international open access journal that provides a forum for important research in the field of aging. The full study is available here: https://www.nature.com/articles/s41514-017-0016-9.